Suivre
David Ridley
David Ridley
Adresse e-mail validée de duke.edu - Page d'accueil
Titre
Citée par
Citée par
Année
Developing drugs for developing countries
DB Ridley, HG Grabowski, JL Moe
Health Affairs 25 (2), 313-324, 2006
2502006
Entry and competition in generic biologics
HG Grabowski, DB Ridley, KA Schulman
Managerial and Decision Economics 28 (4‐5), 439-451, 2007
942007
Distance decreases with differentiation: Strategic agglomeration by retailers
GA Picone, DB Ridley, PA Zandbergen
International Journal of Industrial Organization 27 (3), 463-473, 2009
922009
Pharmaceutical followers
P Arcidiacono, PB Ellickson, P Landry, DB Ridley
International Journal of Industrial Organization 31 (5), 538-553, 2013
842013
Would greater transparency and uniformity of health care prices benefit poor patients?
MK Kyle, DB Ridley
Health Affairs 26 (5), 1384-1391, 2007
652007
Price differentiation and transparency in the global pharmaceutical marketplace
DB Ridley
Pharmacoeconomics 23, 651-658, 2005
642005
The role of government reimbursement in drug shortages
A Yurukoglu, E Liebman, DB Ridley
American Economic Journal: Economic Policy 9 (2), 348-382, 2017
522017
Herding versus Hotelling: Market entry with costly information
DB Ridley
Journal of Economics & Management Strategy 17 (3), 607-631, 2008
512008
The commercial market for priority review vouchers
DB Ridley, SA Régnier
Health Affairs 35 (5), 776-783, 2016
392016
Introduction of European priority review vouchers to encourage development of new medicines for neglected diseases
DB Ridley, AC Sánchez
The Lancet 376 (9744), 922-927, 2010
352010
Impact of Medicaid preferred drug lists on therapeutic adherence
DB Ridley, KJ Axelsen
Pharmacoeconomics 24, 65-78, 2006
312006
Drugs and vaccines for developing countries
A Towse, E Keuffel, HE Kettler, DB Ridley
The Oxford handbook of the economics of the biopharmaceutical industry, 302-310, 2012
272012
No shot: US vaccine prices and shortages
DB Ridley, X Bei, EB Liebman
Health Affairs 35 (2), 235-241, 2016
232016
Priorities for the priority review voucher
DB Ridley
The American journal of tropical medicine and hygiene 96 (1), 14, 2017
222017
Retail zoning and competition
DB Ridley, FA Sloan, Y Song
Working Paper, 2010
222010
Strategic interaction among governments in the provision of a global public good
MK Kyle, DB Ridley, S Zhang
Journal of Public Economics 156, 185-199, 2017
192017
Forecasting market share in the US pharmaceutical market
S Regnier, DB Ridley
nature reviews drug discovery 14 (9), 594-595, 2015
182015
The cost of inefficiency in US hospitals, 1985-1997.
BR Shah, SD Reed, J Francis, DB Ridley, KA Schulman
Journal of Health Care Finance 30 (1), 1-9, 2003
182003
Priority review vouchers to encourage innovation for neglected diseases
HG Grabowski, DB Ridley, JL Moe
Prescribing cultures and pharmaceutical policy in the Asia-Pacific, 2009
172009
Payments, promotion, and the purple pill
DB Ridley
Health economics 24 (1), 86-103, 2015
162015
Le système ne peut pas réaliser cette opération maintenant. Veuillez réessayer plus tard.
Articles 1–20